Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 24, 2001
Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy
A Schneeweiss, R Goerner, M A Hensel, et al.
Breast (Edinburgh, Scotland)
|
March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study
A Mavratzas, S Baek, B Gerber, et al.
Breast Cancer Research and Treatment
|
February 24, 2019
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
R Wuerstlein, R Kates, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U A Nitz, O Gluz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2020
Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)
A J P Clover, F de Terlizzi, G Bertino, et al.
Geburtshilfe Und Frauenheilkunde
|
January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
P A Fasching, T Fehm, S Kellner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
M Martín, S R Stecklein, O Gluz, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 24, 2001
Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy
A Schneeweiss, R Goerner, M A Hensel, et al.
Breast (Edinburgh, Scotland)
|
March 2, 2019
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study
A Mavratzas, S Baek, B Gerber, et al.
Breast Cancer Research and Treatment
|
February 24, 2019
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
R Wuerstlein, R Kates, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U A Nitz, O Gluz, M Christgen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial
O Gluz, S Kuemmel, U Nitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S Loibl, M Untch, N Burchardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 25, 2020
Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019)
A J P Clover, F de Terlizzi, G Bertino, et al.
Geburtshilfe Und Frauenheilkunde
|
January 9, 2015
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
P A Fasching, T Fehm, S Kellner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 17, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy
M Martín, S R Stecklein, O Gluz, et al.
Page
of 7